K180165 is an FDA 510(k) clearance for the Habib EndoHPB. Classified as Unit, Electrosurgical, Endoscopic (with Or Without Accessories) (product code KNS), Class II - Special Controls.
Submitted by Emcision , Ltd. (London, GB). The FDA issued a Cleared decision on March 20, 2018 after a review of 57 days - a notably fast clearance cycle.
This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.4300 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.
View all Emcision , Ltd. devices
NCT01303159
Terminated
Interventional
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
| Condition studied |
Cholangiocarcinoma; Pancreatic Cancer |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Michel Kahaleh, M.D. |
| Sponsor |
Weill Medical College of Cornell University
|
Started 2010-03-01
→
Primary completion 2014-01-13
Primary outcome
Change From Baseline in Bile Duct Stricture Diameter
Secondary outcome
Number of Participants With Adverse Events
View full study on ClinicalTrials.gov